20 Years of SUPRATHEL

1996

Commissioning of the German Center Biomaterial and Organ Replacement Stuttgart-Tübingen, BMOZ for short. An interdisciplinary center with partners from medicine and industry, it conducts research on, inter alia, absorbable membrane, i.e. a synthetic skin substitute.

1997

Launch of the BMBF project to develop a wound dressing for burns with funding that totals over four million German marks.

1998

V16, a new resorbable and highly porous membrane, the later SUPRATHEL®, fulfills its developers’ requirements. ¹

1999

V16 is used for the first time to treat burns at the Marienhospital in Stuttgart. The results are so impressive that the physicians feel it is irresponsible to continue treating burns conventionally.²

2000

“SUPRATHEL®“ secures worldwide patent and brand name protection.

2001

PolyMedics Innovations is founded, taking over the rights to SUPRATHEL®; the other participants are not in pursuing the project further.

2004

CE approval for SUPRATHEL® for use in second-degree burns (2a and 2b) and in donor sites.

2005

SUPRATHEL® receives extended CE approval for use on mixed (second and third) degree. By the year’s end SUPRATHEL® has been used to treat over 1,000 patients.

2007

At the year’s end over 3,000 patients have been treated with SUPRATHEL® and the product is in use in around 15 countries. In Germany, Austria, and Switzerland alone it is used consistently in over 120 clinics.

2008

SUPRATHEL® is launched in France and registered in Mexico. Over 4,000 people have now been treated with SUPRATHEL®.

2009